Pancreatic Cancer Research

ResearcherChemRegen (United States)Active in the last 2 years

Jiongjia Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0908-3880; OpenAlex author ID A5101471919. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 4

  1. Prediction of synergistic gemcitabine-based combination treatment through a novel tumor stemness biomarker NANOG in pancreatic cancer. Co-author DOI 10.1039/d4md00165f↗
  2. Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression. Co-author DOI 10.1007/s10637-020-00998-z↗
  3. PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin β3-KRAS-dependent pancreatic cancer stem cells. Co-author DOI 10.1038/s41598-020-65804-5↗
  4. Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53. Co-author PMID 30906636↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Richard Cashman · 3 shared papers, 2019–2021 · strength 0.63
  2. Guang‐Xiang Liu · 1 shared paper, 2024 · strength 0.26
  3. Xiaofeng Wang · 1 shared paper, 2024 · strength 0.26
  4. Andrew M. Lowy · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.